Return to Home Incidence > Table

Incidence Rates Table

Data Options

Incidence Rate Report by State

Oral Cavity & Pharynx (Late Stage^), 2017-2021

All Races (includes Hispanic), Both Sexes, All Ages

Sorted by CI*Rank
State
 sort alphabetically by name ascending
Age-Adjusted Incidence Rate
cases per 100,000
(95% Confidence Interval)
 sort by rate descending
CI*Rank
(95% Confidence Interval)
 sort by CI rank ascending
Average Annual Count
 sort by count descending
Percent of Cases with Late Stage
 sort by percent late descending
US (SEER+NPCR) 1 7.6 (7.5, 7.6) N/A 30,508 63.7
Utah 3 5.3 (5.0, 5.7) 50 (46, 50) 157 57.1
Nevada 6 5.6 (5.3, 6.0) 49 (45, 50) 211 54.2
Arizona 6 5.7 (5.5, 5.9) 48 (45, 50) 517 59.5
Wyoming 6 5.9 (5.1, 6.8) 47 (34, 50) 43 57.7
New Mexico 3 5.9 (5.5, 6.3) 46 (44, 50) 159 62.9
Alabama 6 6.4 (6.1, 6.7) 45 (40, 47) 412 53.5
California 3 6.6 (6.5, 6.7) 44 (41, 46) 2,998 65.2
Colorado 6 6.7 (6.4, 7.0) 43 (35, 46) 452 63.4
District of Columbia 6 6.8 (5.9, 7.7) 42 (17, 49) 46 65.3
Minnesota 6 6.8 (6.5, 7.1) 41 (33, 45) 482 53.6
Maryland 6 7.0 (6.7, 7.3) 40 (30, 44) 544 63.9
New York 3 7.1 (6.9, 7.2) 39 (32, 42) 1,815 65.1
North Dakota 6 7.1 (6.3, 8.0) 38 (13, 46) 65 57.1
Virginia 6 7.1 (6.9, 7.3) 37 (30, 42) 755 61.6
Texas 3 7.1 (7.0, 7.3) 36 (31, 41) 2,194 62.3
Idaho 3 7.1 (6.6, 7.7) 35 (20, 45) 159 60.6
New Jersey 3 7.1 (6.9, 7.4) 34 (29, 42) 854 64.4
South Dakota 6 7.3 (6.6, 8.1) 33 (11, 46) 79 60.3
Kansas 6 7.4 (7.0, 7.8) 32 (19, 42) 261 62.7
Connecticut 3 7.5 (7.2, 7.9) 31 (18, 40) 366 63.2
Rhode Island 6 7.6 (7.0, 8.3) 30 (8, 43) 111 69.8
Washington 5 7.6 (7.4, 7.9) 29 (19, 35) 706 60.1
Montana 6 7.7 (7.0, 8.4) 27 (6, 43) 111 64.3
Nebraska 6 7.7 (7.2, 8.2) 26 (11, 40) 180 59.4
Delaware 6 7.7 (7.0, 8.4) 25 (7, 43) 105 64.9
Michigan 6 7.7 (7.5, 8.0) 24 (17, 33) 1,022 65.8
Hawaii 3 7.8 (7.2, 8.4) 23 (7, 40) 145 61.2
Illinois 3 7.9 (7.7, 8.1) 22 (15, 29) 1,258 65.6
Oregon 6 8.0 (7.6, 8.3) 21 (10, 32) 439 66.5
Oklahoma 6 8.0 (7.6, 8.4) 20 (10, 31) 376 59.2
Pennsylvania 6 8.0 (7.8, 8.2) 19 (14, 27) 1,403 65.3
Wisconsin 6 8.0 (7.8, 8.3) 18 (11, 29) 627 63.6
New Hampshire 6 8.2 (7.6, 8.8) 17 (3, 34) 161 65.8
Tennessee 6 8.3 (8.0, 8.5) 16 (7, 24) 720 64.1
Alaska 6 8.3 (7.4, 9.3) 15 (2, 39) 68 66.1
Mississippi 6 8.3 (7.9, 8.8) 14 (4, 27) 307 65.1
North Carolina 6 8.5 (8.2, 8.7) 13 (5, 19) 1,103 66.4
Georgia 3 8.5 (8.3, 8.8) 12 (4, 18) 1,057 68.1
Ohio 6 8.6 (8.3, 8.8) 11 (4, 17) 1,314 67.7
South Carolina 6 8.6 (8.3, 8.9) 10 (3, 19) 578 67.4
Iowa 3 8.6 (8.2, 9.0) 9 (3, 21) 346 60.2
Florida 6 8.6 (8.5, 8.8) 8 (4, 14) 2,621 60.5
Vermont 6 8.7 (7.8, 9.6) 7 (1, 33) 78 67.5
Arkansas 6 8.7 (8.2, 9.1) 6 (2, 20) 328 65.6
Missouri 6 8.8 (8.5, 9.1) 5 (3, 15) 689 68.8
Louisiana 3 8.8 (8.4, 9.2) 4 (2, 16) 499 67.2
Maine 6 9.2 (8.6, 9.8) 3 (1, 16) 189 65.4
Kentucky 3 9.4 (9.1, 9.8) 2 (1, 5) 539 67.8
West Virginia 6 10.0 (9.4, 10.6) 1 (1, 3) 254 69.6
Indiana 6
data not available
N/A
data not available
data not available
Puerto Rico 6 4.3 (4.0, 4.6) N/A 185 50.3
Notes:
Created by statecancerprofiles.cancer.gov on 10/12/2024 3:30 pm.

State Cancer Registries may provide more current or more local data.

Data cannot be shown for the following areas. For more information on what areas are suppressed or not available, please refer to the table.
Indiana, Puerto Rico

† Incidence rates (cases per 100,000 population per year) are age-adjusted to the 2000 US standard population (19 age groups: <1, 1-4, 5-9, ... , 80-84, 85+). Rates are for invasive cancer only (except for bladder cancer which is invasive and in situ) or unless otherwise specified. Rates calculated using SEER*Stat. Population counts for denominators are based on Census populations as modified by NCI. The US Population Data File is used for SEER and NPCR incidence rates.

Rates are computed using cancers classified as malignant based on ICD-O-3. For more information see malignant.html.

^ Late Stage is defined as cases determined to be regional or distant. Due to changes in stage coding, Combined Summary Stage (2004+) is used for data from Surveillance, Epidemiology, and End Results (SEER) databases and Merged Summary Stage is used for data from National Program of Cancer Registries databases. Due to the increased complexity with staging, other staging variables maybe used if necessary.
⋔ Results presented with the CI*Rank statistics help show the usefulness of ranks. For example, ranks for relatively rare diseases or less populated areas may be essentially meaningless because of their large variability, but ranks for more common diseases in densely populated regions can be very useful. More information about methodology can be found on the CI*Rank website.

Data not available for this combination of data selections.
Source: SEER and NPCR data. For more specific information please see the table.

Data for the United States does not include data from Indiana.
Data for the United States does not include Puerto Rico.
CI*Rank data for Puerto Rico is not available.

Return to Top